.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Covington
Dow
Teva
Baxter
Fuji
Chubb
AstraZeneca
Healthtrust
US Department of Justice

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Sign Up

« Back to Dashboard

Details for Patent: ➤ Sign Up

Title:Modified release compositions comprising tacrolimus
Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.
Inventor(s): Holm; Per (Vanlose, DK), Norling; Tomas (Lyngby, DK)
Assignee: VELOXIS PHARMACEUTICALS A/S (Copenhagen, DK)
Filing Date:Sep 16, 2015
Application Number:14/855,624
Claims:1. A solid pharmaceutical composition comprising: (a) tacrolimus; (b) hydroxypropyl methylcellulose; (c) lactose; (d) polyethylene glycol 6000; (e) poloxamer 188; and (f) magnesium stearate.

2. The solid pharmaceutical composition of claim 1, wherein less than 20% w/w of the tacrolimus is released from the solid pharmaceutical composition within 0.5 hours, when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium.

3. The solid pharmaceutical composition of claim 1, wherein less than 20% w/w of the tacrolimus is released from the solid pharmaceutical composition within 3 hours, when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium.

4. The solid pharmaceutical composition of claim 2, wherein the weight ratio of polyethylene glycol 6000 to poloxamer 188 is between 1:3 and 10:1.

5. The solid pharmaceutical composition of claim 2, wherein the dosage form is a tablet.

6. The solid pharmaceutical composition of claim 1, wherein the composition releases at most 62% of the tacrolimus in the composition within 15 hours when subjected to an in vitro dissolution test using USP Paddle method at a rotation speed of 50 rpm in a 900 mL aqueous dissolution medium with 0.005% hydroxypropylcellulose which has been adjusted to pH 4.5.

7. The solid pharmaceutical composition of claim 1, wherein the dosage form is a tablet.

8. The solid pharmaceutical composition of claim 3, wherein the dosage form is a tablet.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
McKesson
Citi
Merck
Farmers Insurance
Fish and Richardson
Deloitte
Harvard Business School
Cipla
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot